COCP Relative Valuation
COCP's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, COCP is overvalued; if below, it's undervalued.
Historical Valuation
Cocrystal Pharma Inc (COCP) is now in the Fair zone, suggesting that its current forward PS ratio of 0.00 is considered Fairly compared with the five-year average of -2.56. The fair price of Cocrystal Pharma Inc (COCP) is between NaN to NaN according to relative valuation methord.
Relative Value
Fair Zone
NaN-NaN
Current Price：1.10
Fair
-1.29
PE
1Y
3Y
5Y
0.00
EV/EBITDA
Cocrystal Pharma Inc. (COCP) has a current EV/EBITDA of 0.00. The 5-year average EV/EBITDA is 0.17. The thresholds are as follows: Strongly Undervalued below -0.52, Undervalued between -0.52 and -0.17, Fairly Valued between 0.52 and -0.17, Overvalued between 0.52 and 0.86, and Strongly Overvalued above 0.86. The current Forward EV/EBITDA of 0.00 falls within the Historic Trend Line -Fairly Valued range.
-0.49
EV/EBIT
Cocrystal Pharma Inc. (COCP) has a current EV/EBIT of -0.49. The 5-year average EV/EBIT is -0.71. The thresholds are as follows: Strongly Undervalued below -5.03, Undervalued between -5.03 and -2.87, Fairly Valued between 1.44 and -2.87, Overvalued between 1.44 and 3.60, and Strongly Overvalued above 3.60. The current Forward EV/EBIT of -0.49 falls within the Historic Trend Line -Fairly Valued range.
0.00
PS
Cocrystal Pharma Inc. (COCP) has a current PS of 0.00. The 5-year average PS is 16.62. The thresholds are as follows: Strongly Undervalued below -32.68, Undervalued between -32.68 and -8.03, Fairly Valued between 41.27 and -8.03, Overvalued between 41.27 and 65.93, and Strongly Overvalued above 65.93. The current Forward PS of 0.00 falls within the Historic Trend Line -Fairly Valued range.
0.00
P/OCF
Cocrystal Pharma Inc. (COCP) has a current P/OCF of 0.00. The 5-year average P/OCF is -0.63. The thresholds are as follows: Strongly Undervalued below -5.14, Undervalued between -5.14 and -2.89, Fairly Valued between 1.63 and -2.89, Overvalued between 1.63 and 3.88, and Strongly Overvalued above 3.88. The current Forward P/OCF of 0.00 falls within the Historic Trend Line -Fairly Valued range.
0.00
P/FCF
Cocrystal Pharma Inc. (COCP) has a current P/FCF of 0.00. The 5-year average P/FCF is 0.00. The thresholds are as follows: Strongly Undervalued below 0.00, Undervalued between 0.00 and 0.00, Fairly Valued between 0.00 and 0.00, Overvalued between 0.00 and 0.00, and Strongly Overvalued above 0.00. The current Forward P/FCF of 0.00 falls within the Strongly Undervalued range.
Cocrystal Pharma Inc (COCP) has a current Price-to-Book (P/B) ratio of 1.69. Compared to its 3-year average P/B ratio of 1.21 , the current P/B ratio is approximately 39.29% higher. Relative to its 5-year average P/B ratio of 1.16, the current P/B ratio is about 45.21% higher. Cocrystal Pharma Inc (COCP) has a Forward Free Cash Flow (FCF) yield of approximately -70.36%. Compared to its 3-year average FCF yield of -86.42%, the current FCF yield is approximately -18.59% lower. Relative to its 5-year average FCF yield of -64.01% , the current FCF yield is about 9.92% lower.
1.69
P/B
Median3y
1.21
Median5y
1.16
-70.36
FCF Yield
Median3y
-86.42
Median5y
-64.01
Competitors Valuation Multiple
The average P/S ratio for COCP's competitors is 6.37, providing a benchmark for relative valuation. Cocrystal Pharma Inc Corp (COCP) exhibits a P/S ratio of 0.00, which is -100% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.
Performance Decomposition
1Y
3Y
5Y
Market capitalization of COCP increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.
The secondary factor is the Unknown, contributed 0.00%to the performance.
Overall, the performance of COCP in the past 1 year is driven by Unknown.
People Also Watch
ABTS
Abits Group Inc
5.83USD
0.95%
WETH
Wetouch Technology Inc
1.7USD
8.28%
NRXS
Neuraxis Inc
4.63USD
4.28%
XTIA
XTI Aerospace Inc
1.77USD
4.12%
MIRA
MIRA Pharmaceuticals Inc
1.49USD
0.68%
CCTG
CCSC Technology International Holdings Ltd
0.1422USD
0.71%
COSM
Cosmos Health Inc
0.5186USD
-0.38%
SMSI
Smith Micro Software Inc
0.5833USD
-1.35%
SDOT
Sadot Group Inc
2.41USD
13.68%
Frequently Asked Questions
Is Cocrystal Pharma Inc (COCP) currently overvalued or undervalued?
Cocrystal Pharma Inc (COCP) is now in the Fair zone, suggesting that its current forward PS ratio of 0.00 is considered Fairly compared with the five-year average of -2.56. The fair price of Cocrystal Pharma Inc (COCP) is between NaN to NaN according to relative valuation methord.
What is Cocrystal Pharma Inc (COCP) fair value?
COCP's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average , adjusted by weights. The fair price of Cocrystal Pharma Inc (COCP) is between NaN to NaN according to relative valuation methord.
How does COCP's valuation metrics compare to the industry average?
The average P/S ratio for COCP's competitors is 6.37, providing a benchmark for relative valuation. Cocrystal Pharma Inc Corp (COCP) exhibits a P/S ratio of 0.00, which is -100.00% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.
What is the current P/B ratio for Cocrystal Pharma Inc (COCP) as of Jan 08 2026?
As of Jan 08 2026, Cocrystal Pharma Inc (COCP) has a P/B ratio of 1.69. This indicates that the market values COCP at 1.69 times its book value.
What is the current FCF Yield for Cocrystal Pharma Inc (COCP) as of Jan 08 2026?
As of Jan 08 2026, Cocrystal Pharma Inc (COCP) has a FCF Yield of -70.36%. This means that for every dollar of Cocrystal Pharma Inc’s market capitalization, the company generates -70.36 cents in free cash flow.
What is the current Forward P/E ratio for Cocrystal Pharma Inc (COCP) as of Jan 08 2026?
As of Jan 08 2026, Cocrystal Pharma Inc (COCP) has a Forward P/E ratio of -1.29. This means the market is willing to pay $-1.29 for every dollar of Cocrystal Pharma Inc’s expected earnings over the next 12 months.
What is the current Forward P/S ratio for Cocrystal Pharma Inc (COCP) as of Jan 08 2026?
As of Jan 08 2026, Cocrystal Pharma Inc (COCP) has a Forward P/S ratio of 0.00. This means the market is valuing COCP at $0.00 for every dollar of expected revenue over the next 12 months.